Seven Australian startups will share $15.6 million in funding to accelerate the development of new treatments, diagnostic tools and technologies for dementia and cognitive decline. The investment aims to support early-stage companies working on solutions for a condition that affects hundreds of thousands of Australians.
The funded projects span a range of approaches, from gene editing for childhood dementia to digital tests that could enable earlier detection of cognitive decline. The diversity of the projects reflects the complex nature of dementia and the need for multiple strategies to address it.
Dementia is a leading cause of death in Australia and a major cause of disability among older people. The funding is intended to help these startups advance their research and bring potential solutions closer to clinical use.
Further details about the individual startups and the specific allocation of funds have not been independently verified. The announcement highlights ongoing efforts to tackle dementia through innovation and investment in Australian biotech and health technology.
